Medsite's E-Pharma Marketing Gain Share Methodology Increases Wellspring's Dyrenium Prescriptions; Medsite Pharmaceutical Services Offers a Zero Cost, Zero Risk Option for Mature Therapies with Limited Marketing Resources.

NEW YORK -- Medsite Pharmaceutical Services LLC, a new division of Medsite, today announced the results from its initial pilot gain share program with the WellSpring Pharmaceutical Corporation. After six months of Phase I promotion for Dyrenium100mg(R), a 40-year-old diuretic therapy, a target group, representing 15 percent of Dyrenium prescribing physicians, generated a 40 percent increase in new prescriptions written. These results were established by a promotional evaluation study conducted by IMS Management Consulting Services.

"We are excited by the results of this pilot program with WellSpring, as it validates this new business model for Medsite," said Sundeep Bhan, founder & CEO, Medsite. "This outcome demonstrates how a unique approach to e-pharma marketing, such as Medsite Pharmaceutical Services' gain share methodology, can bring success to mature products that lack marketing support."

Medsite Pharmaceutical Services' gain share model provides a zero cost, zero risk option for pharmaceutical companies seeking to promote brands valued under $150 million by maximizing visibility among physicians and ultimately increasing revenue. For this pilot program, Medsite Pharmaceutical Services implemented a multi-channel marketing campaign to promote Dyrenium. In the next phase of marketing, Medsite Pharmaceutical Services will target approximately 14,000 high value physicians, including the remaining 85 percent of Dyrenium prescribers, as determined by Medsite's predictive modeling and physician profiling capabilities.

"We are very pleased with the physician exposure that Medsite Pharmaceutical Services' gain share program has generated for Dyrenium," said Dr. Robert A. Vukovich, founder and CEO, WellSpring. "Targeted by their demographics, physicians participate in interactive detailing that provides product information about Dyrenium, as well as other diuretic therapies."

Through a blend of proven marketing techniques, Medsite Pharmaceutical Services offers partners the ability to reach over 400,000 physicians in Medsite's established network leveraging Medsite's channels, such as interactive detailing, market research and Medsite Rewards(TM), to reach targeted audiences at multiple points of contact.

For additional information on Medsite Pharmaceutical Services, contact Vivian Pagoulatos, RPH, Senior Vice President at 212-417-9584 or via e-mail at [e-mail].

About Medsite

Medsite Pharmaceutical Services LLC is a division of Medsite Inc. Medsite is the leader in ethical and effective e-pharmaceutical marketing. The company forges strong, long lasting, and mutually beneficial relationships with physicians and the organizations that want to reach them. Medsite's innovative e-marketing solutions, such as Medsite iDetail(R), Interactive Grand Rounds(TM) and Medsite Rewards(TM), have been utilized by pharmaceutical, biotechnology and communications companies including Pfizer, Bristol Myers-Squibb, Novo Nordisk, Wyeth and Cardinal Health.

Medsite is a privately held, venture-backed company with investors including Morgan Stanley Venture Partners, JP Morgan Partners and others. Medsite has received the Deloitte & Touche "Fast 50" Award as one as the fastest growing technology companies in New York (2001, 2004), and the D&T/Forbes "Fast 500" Award. Medsite's headquarters are at 370 Seventh Avenue, New York, NY 10001. The company's telephone number is [phone] and email can be directed to [e-mail]. Additional information can be found at http://solutions.medsite.com.